Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 6/20 | 0.56 |
| ▸ | CCR1 | P32246 | 1/20 | 0.56 |
| ▸ | HTR6 | P50406 | 4/20 | 0.55 |
| ▸ | DRD2 | P14416 | 3/20 | 0.55 |
| ▸ | HTR2A | P28223 | 3/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.51 |
| ▸ | CCR3 | P51677 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SCN1A | P35498 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24070145 | 0.94 | NPY5R (0.60) | DRD4HTR7HTR6DRD2HTR2A | |
| SCHEMBL25759707 | 0.86 | BCHE (0.63) | HTR7CCR1HTR6DRD2HTR2A | |
| SCHEMBL24069062 | 0.84 | HTR7 (0.68) | HTR7CCR1HTR6DRD2HTR2A | |
| SCHEMBL30376178 | 0.83 | HTR7 (0.69) | HTR7SLC6A2SLC6A4SLC6A3CCR3 | |
| SCHEMBL11111481 | 0.83 | HTR7 (0.66) | HTR7CCR1HTR6DRD2HTR2A | |
| SCHEMBL25289791 | 0.81 | HTR7 (0.73) | HTR7CCR1HTR6DRD2HTR2A | |
| SCHEMBL11101165 | 0.81 | HTR7 (0.67) | HTR7CCR1HTR6DRD2HTR2A | |
| Hydrochloric Acid SCHEMBL11111993 | 0.80 | HTR7 (0.67) | HTR7CCR1HTR6DRD2HTR2A | |
| SCHEMBL24069430 | 0.79 | SLC6A2 (0.57) | HTR7SLC6A2SLC6A4SLC6A3CCR3 | |
| SCHEMBL24069429 | 0.79 | SLC6A2 (0.63) | HTR7SLC6A2SLC6A4SLC6A3CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116157124-A | Sulfonamide derivative and pharmaceutical composition for preventing or treating mental diseases containing the same as active ingredient | 大邱庆北尖端医疗产业振兴财团 | 2023-05-23 | — | — | CN | claimed |
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2023-07-06 | — | — | US | disclosed |
| CN-116157124-A | Sulfonamide derivative and pharmaceutical composition for preventing or treating mental diseases containing the same as active ingredient | 大邱庆北尖端医疗产业振兴财团 | 2023-05-23 | — | — | CN | disclosed |
| EP-4159718-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | Daegu-Gyeongbuk Medical Innovation Foundation (KR) | 2023-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | SLC6A2, SLC6A3, SLC6A4 | DRD4 21/4885HTR7 79/4885CCR1 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.